Targeting mitochondrial dysfunction in neurodegenerative disease: Part i

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 4, 2010, Pages 369-385

  Burchell, Victoria S ^a   Gandhi, Sonia ^b   Deas, Emma ^a   Wood, Nicholas W ^a   Abramov, Andrey Y ^a   Plun Favreau, Hélne ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyotropic lateral sclerosis; Bioenergetic dysfunction; Calcium; Huntington's disease; Mitochondria; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DANTROLENE; DIHYDROPYRIDINE; DIMEBON; ROSIGLITAZONE;

AGING; ALZHEIMER DISEASE; BIOENERGY; CALCIUM HOMEOSTASIS; CELL DEATH; CLINICAL RESEARCH; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FAMILIAL DISEASE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SPINOCEREBELLAR DEGENERATION;

AGING; ANIMALS; CALCIUM; CALCIUM METABOLISM DISORDERS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 77949565639     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003652489     Document Type: Review

References (124)

1. Harman D. The free radical theory of aging: effect of age on serum copper levels. J Gerontol 1965;20:151-153
2. Yen WL, Klionsky DJ. How to live long and prosper: autophagy, mitochondria, and aging. Physiology (Bethesda) 2008;23:248-262
3. Jones DP, Mody VC, Carlson JL, et al. Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radic Biol Med 2002;33:1290-1300
4. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005;39:359-407
5. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795
6. Mackenzie JA, Payne RM. Mitochondrial protein import and human health and disease. Biochim Biophys Acta 2007;1772:509-523
7. Bowling AC, Mutisya EM, Walker LC, et al. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993;60:1964-1967
8. Xiong J, Camello PJ, Verkhratsky A, Toescu EC. Mitochondrial polarisation status and [Ca2+]i signalling in rat cerebellar granule neurones aged in vitro. Neurobiol Aging 2004;25:349-459
9. Qian T, Herman B, Lemasters JJ. The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol Appl Pharmacol 1999;154:117-125
10. Schon EA, Gilkerson RW. Functional complementation of mitochondrial DNAs: mobilizing mitochondrial genetics against dysfunction. Biochim Biophys Acta 2009: published online17 July 2009, doi:10.1016/j.bbagen.2009.07.007
11. Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002;32:797-803
12. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005;120:483-495
13. Ghafourifar P, Richter C. Nitric oxide synthase activity in mitochondria. FEBS Lett 1997;418:291-296
14. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007;10:1355-1360
15. Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 2003;23:5088-5095
16. Abramov AY, Canevari L, Duchen MR. beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004;24:565-575
17. Berg D, Youdim MBH, Riederer P. Redox imbalance. Cell Tissue Res 2004;318:201-213
18. Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol 2009;256(Suppl):9-17
19. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 2006;545:39-50
20. Choe M, Jackson C, Yu BP. Lipid peroxidation contributes to age-related membrane rigidity. Free Radic Biol Med 1995;18:977-984
21. Raess BU, Keenan CE, McConnell EJ. Effects of 4-OH-2,3-trans-nonenal on human erythrocyte plasma membrane Ca2+ pump and passive Ca2+ permeability. Biochem Biophys Res Commun 1997;235:451-454
22. Pope S, Land JM, Heales SJR. Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? Biochim Biophys Acta 2008;1777:794-799
23. Ghosh R, Mitchell DL. Effect of oxidative DNA damage in promoter elements on transcription factor binding. Nucleic Acids Res 1999;27:3213-3218
24. Cosi C, Marien M. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res 1998;809:58-67
25. Yu S-W, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002;297:259-263
26. Swerdlow RH, Parks JK, Cassarino DS, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997;49:918-925
27. Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 2007;85:3416-3428
28. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84
29. Canet-Avilés RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 2004;101:9103-9108
30. Wood-Kaczmar A, Gandhi S, Yao Z, et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PloS ONE 2008;3:e2455. Published online 18 June 2008, doi:10.1371/journal.pone.0002455
31. Dagda RK, Cherra SJ, Kulich SM, et al. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 2009;284:13843-13855
32. Liou AKF, Leak RK, Li L, Zigmond MJ. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol Dis 2008;32:116-124
33. Heo HY, Park J-M, Kim C-H, et al. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 2009: published online 19 September 2009, doi:10.1016/j. yexcr.2009.09.014
34. Sämann J, Hegermann J, Von Gromoff E, et al. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 2009;284:16482-16491
35. Wang H, Lim PJ, Karbowski M, Monteiro MJ. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet 2009;18:737-752
36. Van Roon-Mom WMC, Pepers BA, 'T Hoen PAC, et al. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease. BMC Mol Biol 2008;9:84. Published online 9 October 2008, doi:10.1186/1471-2199-9-84 (Pubitemid 352762900)
37. Yim MB, Yim HS, Chock PB, Stadtman ER. Enhanced free radical generation of FALS-associated Cu, Zn-SOD mutants. Neurotox Res 1999;1:91-97
38. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584
39. Yao JK, Wengenack TM, Curran GL, Poduslo JF. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res 2009;34:102-108
40. Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009;30:1574-1586
41. Shen C, Chen Y, Liu H, et al. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem 2008;283:17721-17730
42. Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann NY Acad Sci 2008;1147:395-412
43. CARE-HD. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404
44. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550
45. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64:938-944
46. Ranen NG, Peyser CE, Coyle JT, et al. A controlled trial of idebenone in Huntington's disease. Mov Disord 1996;11:549-554
47. Gutzmann H, Kühl K-P, Hadler D, Rapp MA. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002;35:12-18
48. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003;61:1498-1502
49. Schulz JB, Di Prospero NA, Fischbeck K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol 2009;256(Suppl):42-45
50. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001;276:4588-4596
51. Jauslin ML, Meier T, Smith RA, Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003;17:1972-1974
52. Tauskela JS. MitoQ-a mitochondria-targeted antioxidant. IDrugs 2007;10:399-412
53. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin Ther Targets 2009;13:319-329
54. Block ML. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neuroscience 2008;9(Suppl 2):S8. Published online 3 December 2008, doi:10.1186/ 1471-2202-9-S2-S8
55. Yokoyama H, Yano R, Aoki E, et al. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metab Brain Dis 2008;23:335-349
56. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278
57. Swerdlow RH. Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem. Antioxid Redox Signal 2007;9:1591-1603
58. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:14670-14675
59. Di Donato S. Multisystem manifestations of mitochondrial disorders. J Neurol 2009;256:693-710
60. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192
61. Langston J, Ballard P, Tetrud J, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
62. Bougria M, Vitorica J, Cano J, Machado A. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes. Eur J Pharmacol 1995;291:407-415
63. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 1985;62:389-394
64. Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997;753:157-162
65. Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008;283:9089-9100
66. Benchoua A, Trioulier Y, Zala D, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 2006;17:1652-1663
67. Crouch PJ, Blake R, Duce JA, et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 2005;25:672-679
68. Schapira AH. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1999;1410:159-170
69. Gimenez-Cassina A, Lim F, Cerrato T, et al. Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. J Biol Chem 2009;284:3001-3011
70. Herrero-Mendez A, Almeida A, Fernandez E, et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 2009;11:742-752
71. Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging (2007) 9:223-233
72. Tabrizi SJ, Workman J, Hart PE, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 2000;47:80-86
73. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008;105:11364-11369
74. Andres-Mateos E, Perier C, Zhang L, et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 2007;104:14807-14812
75. Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 1988;45:836-840
76. Albers DS, Augood SJ, Park LC, et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 2000;74:878-881
77. Aksenov MY, Aksenova MV, Payne RM, et al. The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer's and Pick's disease. Exp Neurol 1997;146:458-465
78. Harr SD, Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol 1995;54:38-41
79. Gandhi S, Wood-Kaczmar A, Yao Z, et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 2009;33:627-638
80. Blass JP. A new approach to treating Alzheimer's disease. Ann NY Acad Sci 2008;1147:122-128
81. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006;67:1262-1264
82. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebocontrolled pilot trial. Neurology 2003;61:925-930
83. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2¢dG. Neurology 2006;66:250-252
84. Moreira PI, Santos MS, Seiça R, Oliveira CR. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007;257:206-214
85. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-958
86. Scheele C, Nielsen AR, Walden TB, et al. Altered regulation of the PINK1 locus: a link between Type 2 diabetes and neurodegeneration? FASEB J 2007;21:3653-3665
87. Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009;29:954-963
88. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127:59-69
89. Wu Z, Boss O. Targeting PGC-1alpha to control energy homeostasis. Expert Opin Ther Targets 2007;11:1329-1338
90. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634
91. Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci 2009;32:249-256
92. Nicholls DG, Budd SL. Neuronal excitotoxicity: the role of mitochondria. Biofactors 1998;8:287-299
93. White RJ, Reynolds IJ. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 1996;16:5688-5697
94. Tymianski M, Charlton MP, Carlen PL, Tator CH. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 1993;13:2085-2104
95. Brennan AM, Suh SW, Won SJ, et al. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci 2009;12:857-863
96. Randall RD, Thayer SA. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J Neurosci 1992;12:1882-1895
97. Khodorov B. Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones. Prog Biophys Mol Biol 2004;86:279-351
98. Abramov AY, Duchen MR. Mechanisms underlying the loss of mitochondrial membrane potential in glutamate excitotoxicity. Biochim Biophys Acta 2008;1777:953-964
99. Abramov AY, Duchen MR. Impaired mitochondrial bioenergetics determines glutamate-induced delayed calcium deregulation in neurons. Biochim Biophys Acta 2009: published online 17 August 2009, doi:10.1016/j.bbagen.2009.08.002
100. Bu J, Sathyendra V, Nagykery N, Geula C. Age-related changes in calbindin-D28k, calretinin, and parvalbumin-immunoreactive neurons in the human cerebral cortex. Exp Neurol 2003;182:220-231
101. Surmeier DJ, Guzman JN, Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium 2010: published online 6 January 2010, doi:10.1016/j.ceca.2009.12.003
102. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004;427:801
103. Buckingham SD, Kwak S, Jones AK, et al. Edited GluR2, a gatekeeper for motor neurone survival? Bioessays 2008;30:1185-1192
104. Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993;90:567-571
105. Tang T-S, Tu H, Chan EYW, et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor Type 1. Neuron 2003;39:227-239
106. Liu J, Tang T-S, Tu H, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia Type 2. J Neurosci 2009;29:9148-9162
107. Chen X, Tang T-S, Tu H, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia Type 3. J Neurosci 2008;28:12713-12724
108. Jaiswal MK, Zech W-D, Goos M, et al. Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neuroscience 2009;10:64. Published online 22 June 2009, doi:10.1186/1471-2202-10-64
109. Zhou J, Yi J, Fu R, et al. Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis. J Biol Chem 2010;285:705-712
110. Marambaud P, Dreses-Werringloer U, Vingtdeux V. Calcium signaling in neurodegeneration. Mol Neurodegeneration 2009;4:20. Published online 6 May 2009, doi:10.1186/1750-1326-4-20
111. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006:CD003154, doi:10.1002/ 14651858.CD003154
112. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-618
113. O'Brien JT. A promising new treatment for Alzheimer's disease? Lancet Neurol 2008;7:768-769
114. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-1086
115. Guo H, Lai L, Butchbach MER, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 2003;12:2519-2532
116. Boston-Howes W, Williams EO, Bogush A, et al. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol 2003;213:229-237
117. Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 1990;87:4078-4082
118. Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006;1762:373-380
119. McGill JK, Beal MF. PGC-1alpha, a new therapeutic target in Huntington's disease? Cell 2006;127:465-468
120. Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992;360:672-674
121. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72
122. Deas E, Plun-Favreau H, Wood NW. PINK1 function in health and disease. EMBO Mol Med 2009;1:152-165
123. Johnson MA, Kuo YM, Westaway SK, et al. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinaseassociated neurodegeneration. Ann NY Acad Sci 2004;1012:282-298
124. Bosveld F, Rana A, Van Der Wouden PE, et al. De novo CoA biosynthesis is required to maintain DNA integrity during development of the Drosophila nervous system. Hum Mol Genet 2008;17:2058-2069